balloon valvotomy

balloon valvotomy

A transiently popular technique for managing aortic valve stenosis.

Outcomes
Mortality at 18 months is 60% (similar to untreated population); event-free survival at 2 years is 20%.
 
Pros
Provides symptomatic relief without surgery.
 
Cons
High (> 10%) rate of complications: stroke, aortic rupture, aortic regurgitation, vascular injury, death.
References in periodicals archive ?
Objective: To determine the short term and three months' echocardiographic outcomes of percutaneous mitral balloon valvotomy (PMBV) in mitral stenosis patients with low Wilkin's score in a medical teaching institution.
Determinants of successful balloon valvotomy in infants with critical pulmonary stenosis or membernous pulmonary atresia with intact ventricular septum.
Determinants of successful balloon valvotomy in infants with critical pulmonary stenosis or membranous pulmonary atresia with intact ventricular septum.
Echocardiographic Assessment of Commissural Calcium: A Simple Predictor of Outcome After Percutaneous Mitral Balloon Valvotomy. Journal of the American College of Cardiology.
In patients with pulmonary artery pressures or valve gradients above these values, percutaneous balloon valvotomy or surgical intervention is recommended, even for patients with apparently moderate mitral stenosis at rest (1, 9).
Balloon valvotomy has been done during pregnancy However, it's not ideal because when the balloon is blocked across the aortic valve, there's no cardiac output for several seconds.
McCrindle BW, Blackstone EH, Williams WG, Sittiwangkul R, Spray TL, Azakie A, et al Are outcomes of surgical versus transcatheter balloon valvotomy equivalent in neonatal critical aortic stenosis?.
Long-term clinical and echocardiographic results after successful mitral balloon valvotomy and predictors of long-term outcome.
Regression of significant tricuspid regurgitation after mitral balloon valvotomy for severe mitral stenosis.
However, the development of percutaneous mitral balloon valvotomy (PMBV) by Inoue in 1984, it emerged as a treatment of choice for selected patients with mitral valve stenosis4.